rss
Eur J Hosp Pharm doi:10.1136/ejhpharm-2012-000176
  • Research
  • Original research

Information leaflets for patients with hepatitis C receiving treatment with triple therapy

  1. María Sanjurjo-Saez
  1. Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain;
  1. Correspondence to Dr Inés Yeste-Gómez, Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Calle Dr. Esquerdo 46, 28007 Madrid, Spain; mines.yeste{at}salud.madrid.org

Abstract

The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article